툴젠

199800KOSDAQ자연과학 및 공학 연구개발업

49.1 / 100

Reference Date: 2026-07-24

Financial Score16.5 / 40

News Sentiment16.6 / 25

Momentum4.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Declined 13.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Toolgen specializes in gene-editing R&D, patent monetization, and the development of therapeutics and functional seeds using CRISPR/Cas9 and other technologies. As the world's only company to develop three types of gene-editing tools (ZFN, TALEN, CRISPR/Cas9), it leads in therapeutic drug development (e.g., TGT-001, TG-wAMD) and functional crop seed innovation (e.g., high-oleic soybeans, disease-resistant potatoes).

Number of Employees

66people

Average Salary

72.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

6.69Industry Average 2.520.0Point

2.7x industry avg (risky)

ROE

-64.34Industry Average -32.093.5Point

2.0x industry avg (excellent)

Debt Ratio

2.89Industry Average 7.316.5Point

Half of industry avg (excellent)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲13.7% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼17.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -44.8% (improving, 3yr)

Detailed News Sentiment

4 totalPositive 2Neutral 1Negative 1Average Sentiment Score 66.2

Positive
바이오텍 대표들 자사주 매입 러시…이달에만 세 곳
바이오텍 대표들의 자사주 매입이 증가함에 따라 툴젠의 주가에 긍정적 영향을 미치고 있다.
Neutral
[기자수첩] 주가 급락 때 갈린 바이오 IR의 태도
바이오 기업들의 주가 하락에 대한 다양한 대응 방식을 다루지만, 특정 종목 툴젠에 대한 직접적인 영향은 명시되지 않았습니다.
Negative
툴젠, 특허전 ‘실탄’ 확보 비상…주가 하락에 증자액 축소 우려
툴젠의 CRISPR 특허 대응 유상증자 계획이 주가 하락으로 인해 축소 우려가 제기되어 부정적 영향이 예상됩니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 41,500Won52-week high 138,20052-week low 27,000

1-month return1.0Point

1m -13.72% (falling)

Volume trend2.0Point

Volume flat

Detailed Disclosure

7 totalPositive 1Neutral 6Negative 0

Positive[기재정정]주요사항보고서(유상증자결정)2026-07-22
Neutral[기재정정]증권신고서(지분증권)2026-07-22
Neutral[기재정정]증권신고서(지분증권)2026-07-20
Neutral주식등의대량보유상황보고서(일반)2026-07-08
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-08